Welcome to our dedicated page for Glucotrack SEC filings (Ticker: GCTK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Glucotrack's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Glucotrack's regulatory disclosures and financial reporting.
GlucoTrack, Inc. entered into a Purchase Agreement and Registration Rights Agreement with Sixth Borough Capital Fund, LP under which the investor committed to purchase up to $20.0 million of the company's common stock, subject to conditions. The facility permits intraday purchases subject to a daily dollar cap of $1,000,000 and a volume limit tied to 100% of five-day average trading volume. Intraday purchases price at the greater of 95% of the lowest intraday trading price or the prior business day closing sale price. The company may pay a Commitment Fee in cash, shares, or pre-funded warrants; if paid in securities those shares will be priced based on a one-day or five-day closing price metric. GlucoTrack must file a registration statement within 15 days covering the commitment fee shares and the maximum purchase shares and use best efforts to have it declared effective within 45 days and to keep it continuously effective for resale until obligations are satisfied.
Glucotrack, Inc. filed a Form S-8 to register 124,555 additional shares of its common stock for issuance under the Glucotrack, Inc. 2024 Equity Incentive Plan. These additional shares reflect an amendment increasing the plan’s maximum aggregate share limit to 125,000, effective May 22, 2025, as adjusted for the company’s one-for-sixty reverse stock split effective June 13, 2025.
The filing uses General Instruction E of Form S-8 to add to a prior S-8 that originally covered 535,127 shares, which were subsequently adjusted to 26,757 and then 445 shares through earlier reverse stock splits. The company also incorporates by reference its recent annual, quarterly, and current reports and related charter and plan documents.
GlucoTrack, Inc. (GCTK) 10-Q highlights key liquidity, capital-raising and equity-structure actions through June 30, 2025. The company reported cash and cash equivalents of $9,555 and continued operating losses, with multiple periods showing losses (examples include $11,589, $7,416, $4,756, $4,489 reflected across periods). Share count rose materially to 899,410 shares outstanding as of June 30, 2025 from 13,409 at 12/31/2024 following public offerings, private placements and warrant exchanges.
The company completed a February 2025 1-for-20 reverse split and a June 2025 1-for-60 reverse split, and stockholders approved increasing authorized common shares from 100,000,000 to 250,000,000. Financing activity included at-the-market sales and registered offerings generating net proceeds such as $4,320, $3,643, and a private placement raising approximately $500. Derivative warrant liabilities changed, with a June 30, 2025 reported balance movement (fair value adjustments noted). Management states it plans to finance operations via equity or debt and notes there is no assurance of obtaining sufficient financing to continue as a going concern.
GlucoTrack (NASDAQ:GCTK) filed an 8-K announcing the issuance of a press release on June 25, 2025. However, the actual content of the press release is not included in this filing. The 8-K serves only as a notice under Regulation FD that a press release was issued and is being furnished as Exhibit 99.1. The filing was signed by Paul Goode, Chief Executive Officer.
The actual material information or substance of the press release cannot be analyzed as it is not provided in this filing.